Zentalis Pharmaceuticals (ZNTL)
(Delayed Data from NSDQ)
$1.34 USD
-0.04 (-2.90%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $1.35 +0.01 (0.75%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth C Momentum F VGM
Fundamental Charts
About Return on Equity (TTM)
Zentalis Pharmaceuticals, Inc.'s return on equity, or ROE, is -65.48% compared to the ROE of the Medical - Biomedical and Genetics industry of -62.65%. While this shows that ZNTL has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
ZNTL 1.34 -0.04(-2.90%)
Will ZNTL be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ZNTL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ZNTL
Zentalis Pharmaceuticals (ZNTL) Loses -46.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Zentalis Pharmaceuticals (ZNTL) Upgraded to Strong Buy: What Does It Mean for the Stock?
ZNTL: What are Zacks experts saying now?
Zacks Private Portfolio Services
New Strong Buy Stocks for January 9th
Biotech Stock Roundup: GILD, NUVL Stocks Surge on Study Data, MRNA Down on Updates
Zentalis Stock Up as FDA Lifts Partial Hold on Cancer Drug Studies
Other News for ZNTL
Zentalis management to meet with Oppenheimer
ZNTL Hosts Investor Meetings in Mid-July | ZNTL Stock News
Zentalis management to meet with Oppenheimer
Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | ZNTL ...
Zentalis Pharmaceuticals Holds 2025 Annual Stockholders Meeting